Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Discussion This study assessed prescribing patterns of GLP-1 RAs in Region Stockholm, Sweden, between 2019 and 2023, with a focus on off-label prescribing
The program typically excludes those with commercial insurance and usually requires documentation such as proof of income and, if applicable, proof of denial of Medicaid or other government coverage
The regions growth is supported by a rapidly escalating burden of type 2 diabetes and obesity, particularly in urban centers
It's time to step into the spotlight and shine as the best version of yourself
Experts do say that the findings hint at further benefits of the drug beyond diabetes and obesity
Over 75% of health plans and over 50% of employers are moderately or very concerned about off-label use of GLP-1s approved for type 2 diabetes, but awareness of how much current spend is off-label is notably lower: nearly half of employers and a quarter of health plans are unsure
